Breast Cancer Management at the Crossroads: The imaging (R)evolution is now

The landscape of breast cancer care is undergoing a paradigm shift. Our role within the clinical team and the tumor board has fundamentally shifted. For decades, radiologists were primarily gatekeepers of detection. However, the trajectory is changing rapidly. By 2026, we will be the ones determining who requires treatment and who does not—moving beyond mere detection or screening to actively shaping every decision for the patient. In this new era, radiologists are no longer just observers; we are now at the very heart of the process.

The Shift from Detection to Decision-Making

Traditionally, the workflow focused on identifying lesions and referring them for surgery. Today, the integration of Artificial Intelligence (AI) and advanced imaging techniques like MRI with contrast has altered this dynamic. We are seeing a reduction in missed cancers, particularly in patients with dense breasts, where mammography alone is insufficient.

This transition represents more than an optimization; it is a complete transformation of the clinical pathway. The radiologist's ability to predict complete response early through AI allows for de-escalation of surgery when appropriate. Instead of systematic intervention for every small cancer, the team can choose between surgery, vacuum-assisted excision (VAE), or cryoablation. This approach minimizes patient burden while ensuring optimal oncological outcomes.

Personalized Screening and Risk Stratification

The future of screening lies in personalization. Initiatives like the MY PEBS trial is highlighting that not all patients carry equal risk. By 2026, AI-driven risk stratification will enable highly personalized screening programs. Unlike traditional SNP tests, advanced imaging combined with AI can identify high-risk individuals with greater precision, ensuring resources are directed where they are needed most.

Furthermore, the collaboration between radiology and oncology has never been stronger. If imaging predicts a complete response to neoadjuvant therapy, surgery may be omitted entirely. This synergy between imaging, medical oncology, and surgery exemplifies the "imaging (R)evolution."

Embracing the New Workflow

Integrating AI safely into the clinical workflow requires trust and a willingness to adapt. While challenges regarding reimbursement and cost remain, particularly in regions like France where implementation costs are currently borne by the project, the long-term benefits of reduced unnecessary operations and improved patient care outweigh the initial hurdles.

As we move into 2025 and beyond, the radiologist's position is central to the multidisciplinary team. We are helping surgeons, who are increasingly oncoplastic specialists, tailor treatments that respect both tumor biology and patient quality of life. This is not just a technological upgrade; it is a fundamental redefinition of our profession.

The future of breast cancer management is here. It is defined by collaboration, precision, and a commitment to patient-centered care where imaging drives every critical decision.